Lipid-based nanoparticles are evolving-faster, safer and more precise than ever. With traditional LNPs struggling to reach tissues beyond the liver, the industry is doubling down on next generation technologies for extra-hepatic. In 2024 alone, Novo Nordisk invested $600M in NanoVation to push genetic medicines further, while Nanite and Saliogen joined forces to pioneer non-viral, lung-targeting nanoparticles.

Formerly known as the Next Gen Lipid-Based Nanoparticle Delivery Summit, the summit is the only industry-dedicated event laser-focused on extrahepatic targeting, delivery efficiency and scalable manufacturing for mRNA, siRNA, DNA and gene therapies.

Time: 8:00 AM – 4:30 PM

Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States

Prices: USD 2599.00 – USD 5097.00

Speakers: Bin Wu, Founder and Chief Executive Officer, Cytodigm, Gaurav Gulati, Senior Formulation Scientist, University of Cincinnati, Gilles Divita, CEO, Divincell, Kanika Suri, Scientist, Drug Product and Device Development, CMC, Takeda, Ketaki Deshmukh, Senior Scientist, Novo Nordisk, Mansoor Amiji, University Distinguished Professor, Northeastern University,  and more